1 October 2026

PayPoint Plc (the “Company”)
Total Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority Disclosure Guidance and Transparency Rule 5.6.1.

As of 30 September 2026, the Company’s share capital consisted of 58,655,795 ordinary shares of £0.003611 each. Each ordinary share carries the right to one vote in relation to all circumstances at general meetings of the Company. The Company does not hold any shares in treasury.

The above figure of 58,655,795 may be used by shareholders and others with notification obligations as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Enquiries:

PayPoint Plc

Sophie Line, on behalf of Indigo Corporate Secretary Limited, Company Secretary,
+44 (0)7927 132060

Steve O’Neill, Chief Marketing and Corporate Affairs Officer, +44 (0)7919 488066

LEI Number: 5493004YKWI8U0GDD138

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

ZUG, Switzerland, October 1, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on October 1, 2026. This 5-year campaign aims to accelerate research breakthroughs, improve access to care, and create a future where no one lives with the uncertainty of multiple sclerosis (MS). By bringing together people affected by MS, researchers, healthcare leaders, advocates, and supporters, the campaign seeks to translate scientific progress into meaningful advances in treatment and care, while strengthening the resources and support available to the MS community. Oculis’ sponsorship reflects a shared commitment to advancing innovation, addressing unmet needs, and improving the lives of people affected by MS.

As part of the campaign, the National Multiple Sclerosis Society is convening respected MS thought leaders, health industry and corporate leaders, researchers, and healthcare providers across three programs: a CEO Roundtable, Big Bets for Breakthroughs: The MS Research Symposium, and the Campaign to End MS Gala.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said, “Our sponsorship of the National MS Society’s Campaign to End MS marks the beginning of what we believe will be a long-term partnership with an organization that has spent 80 years advancing research and care for people living with MS. We share the Society’s commitment to accelerating progress for people affected by MS and, through our Privosegtor development program, we are working to advance a much-needed neuroprotective treatment option for patients experiencing optic neuritis and acute MS relapses.”

Oculis is currently developing Privosegtor with the aim to provide the first neuroprotective therapy for optic neuritis (ON), a common MS relapse type and often the first manifestation of MS, with broad potential applicability in other neuro-ophthalmic and neurological diseases. Following the successful Phase 2 ACUITY trial, Oculis launched the PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON. In addition, following positive pre-IND FDA feedback supporting Privosegtor’s development strategy for treating acute MS relapses, Oculis is on track to submit the related IND in the fourth quarter of this year. The Company plans to host an R&D Day in Q4 to provide updates on its pipeline and development programs, including Privosegtor.

– Ends –

About Privosegtor
Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina, including GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis, and multiple sclerosis (MS), where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility (clinical function disability) in the MS model.

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) as well as Orphan Drug designation from both the FDA and the EMA for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION). Building on the ACUITY Phase 2 dataset in ON and constructive FDA pre-IND feedback, Oculis is also planning an IND submission for Privosegtor for the treatment of acute MS relapses.

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.

About MS

MS is a chronic immune-mediated disease affecting approximately 2.8 million people worldwide, including around 850,000 in the U.S. alone.1-3 It is currently managed using immunomodulators or disease-modifying therapies (DMTs) that reduce the rate of relapses and therefore related relapse-associated worsening (RAW). However, relapses still persist for many patients, with an estimated 170,000 MS relapses occurring each year in the U.S.4 During an acute relapse, neurologists commonly use a short course of high-dose corticosteroids to reduce inflammation and shorten the episode, as is also standard of care in optic neuritis. However, corticosteroids do not mitigate the long-term disability, and recovery from relapses is often incomplete, such as in optic neuritis. There are currently no neuroprotective therapies approved for MS relapses, and there remains an urgent unmet medical need for treatments that can prevent central nervous system damage.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

About the National Multiple Sclerosis Society
The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives.
        
Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotection therapy for optic neuritis and its potential broad applicability across neurology, including in acute MS relapses, the initiation, enrollment, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Results of earlier stage clinical trials may not be replicated in subsequent clinical trials. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

  1. MS National Society
  2. Wallin et al., 2019, The prevalence of MS in the United States: A population-based estimate using health claims data – PubMed
  3. McGinley et al., 2021, Diagnosis and Treatment of Multiple Sclerosis: A Review – PubMed
  4. Multiple sources on relapse rate (ARR) including: Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study – PubMed

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey, 1 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares 30 September 2026
Number of Shares purchased 24,025 Class A Shares
Highest price/lowest price paid £14.68 / £14.62
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 37,571,466‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 37,571,466 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

ICG Enterprise Trust plc (the “Company”)

1 October 2026

Total Voting Rights

In accordance with the FCA’s Disclosure Guidance and Transparency Rule 5.6.1R, the Company announces as follows.

At the close of business on 30 September 2026, the Company had 63,554,192 Ordinary shares in issue, of which 3,352,560 were held in Treasury. Therefore, the total number of voting rights in the Company is 60,201,632.

The above figure 60,201,632 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

Neuberger Private Equity Partners Limited Announces Total Voting Rights

St Peter Port, Guernsey 1 October 2026

In accordance with DTR 5.6.1R, Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) notifies the market of the following:

Class of Share Number in issue as at 30 September 2026 Voting Entitlement pursuant to the Articles of Incorporation Number held in Treasury as at 30 September 2026 Voting Rights as at 30 September 2026
Class A Ordinary 40,721,874 May attend and vote at general meetings 3,150,408 37,571,466
Class A Shareholders have the right to receive notice of general meetings of the Company and shall have the right to attend and vote at all general meetings.
B Shares 10,000 Except in certain circumstances, do not carry voting rights 0 0
Class B Shareholders do not have the right to receive notice of or have the right to attend and vote at any general meetings. However, there are limited circumstances where the Company shall not act, without the prior approval of the Class B Shareholders by ordinary resolution passed at a separate general meeting of the Class B Shareholders. Separately, the Directors shall, at appropriate times carry out the FPI Test and, if they determine that the US Shareholding Percentage had exceeded the FPI Specified Percentage as at such FPI Calculation Date, with effect from the date on which the Directors make such determination, the Class B Shares in issue shall, with respect to any Director Resolution, carry a positive number of voting rights as per the calculation referenced in the Articles.
Total Voting Rights       37,571,466

For further information, please contact:

NBPE Investor Relations +44 20 3214 9002
Luke Mason NBPrivateMarketsIR@nb.com
   
Oak Group +44 1481 723450
  NBPEP@oak.group

About Neuberger Private Equity Partners Limited

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger’s investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again this past year, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards.
Data as of March 31, 2026.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

All Neuberger figures are as of March 31, 2026, unless otherwise noted, and are subject to change without notice. The firm data, including employees and assets under management, reflect the collective data of the various affiliated investment advisors who are subsidiaries of Neuberger Berman Group LLC. The company history/timeline includes the history of all the company’s subsidiaries, including predecessor companies and acquisitions.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

ICG plc (the “Company”)

1 October 2026

Total Voting Rights

In accordance with the FCA’s Disclosure Guidance and Transparency Rule 5.6.1R, the Company announces as follows.

At the close of business on the 30 September 2026, the Company had 275,363,297 Ordinary Shares in issue and 15,280,825 Ordinary Non-Voting shares in issue.

The Company does not hold any shares in Treasury. Therefore, the total number of voting rights in the Company is 275,363,297, and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

  • New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3
  • Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care4,5
  • With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide1-3

Basel, 1 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust anatomical improvements in untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes.1-3

In the nAMD and DME cohorts of the study, vision and central subfield thickness (CST) improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after 12 months of Vabysmo treatment.1,2 In RVO, both subtypes of the disease showed improvements in efficacy in people treated with Vabysmo.3 In the central/hemi-RVO cohort, vision and CST improved in both previously untreated and treated eyes after six months of Vabysmo therapy.3 In the branch RVO cohort, vision and CST improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after six months of Vabysmo treatment.3 The data are being presented at the EURETINA 2026 Annual Meeting in Vienna, Austria.

“These real-world results underscore how the efficacy and safety observed in our pivotal Vabysmo studies translate directly into routine clinical practice globally,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The sustained visual improvements and meaningful anatomical drying seen in the VOYAGER study reinforce the role of Vabysmo in helping to address important unmet needs for patients with retinal conditions.”

“In daily clinical practice, we manage diverse patient populations with complex treatment histories who don’t always mirror the strict entry criteria of controlled Phase III trials.” said Professor Robyn Guymer, Chair of the VOYAGER Steering Committee and Deputy Director of the Centre for Eye Research Australia. “The latest VOYAGER data give physicians from across the world the confidence that Vabysmo delivers sustained visual gains, meaningful anatomical drying, and an established safety profile in everyday practice – whether a patient is starting treatment for the first time or transitioning from another therapy.”

The new VOYAGER real-world data in nAMD, DME and RVO are consistent with previous Phase III study results and demonstrate the effectiveness, durability and safety of Vabysmo across diverse global practices.1-3 Across all cohorts of the study, the presence of subretinal fluid (SRF) or intraretinal fluid (IRF) was consistently reduced in previously untreated and treated eyes.1-3 In the nAMD and DME groups, fewer Vabysmo injections were received during months 7-12 compared with months 1-6, suggesting extension of treatment intervals.1,2

  Mean change in visual acuity (VA)
Early Treatment Diabetic Retinopathy Study (ETDRS) letters
Mean change in central subfield thickness (CST)
µm
Presence of subretinal fluid (SRF)
% of eyes
Presence of intraretinal fluid (IRF)
% of eyes
nAMD (after 12 months of Vabysmo treatment)1
No prior treatment +4.6 –110.5 72.1→25.3 48.5→20.6
Previously treated -0.1 -26.1 61.6→37.9 35.4→25.0
DME (after 12 months of Vabysmo treatment)2
No prior treatment +8.2 -127.8 26.5→6.8 87.3→58.1
Previously treated +2.7 -71.3 22.1→9.3 80.5→68.1
Branch RVO (after 6 months of Vabysmo treatment)3
No prior treatment +10.0 -171.3 36.3→11.8 83.8→50.0
Previously treated +2.0 -59.0 15.9→6.6 82.6→80.3
Central/hemi-RVO (after 6 months of Vabysmo treatment)3
No prior treatment +16.6 -287.4 50.7→9.8 85.7→29.4
Previously treated +3.9 -63.4 14.9→10.3 89.4→74.4

In VOYAGER, the Vabysmo safety profile was generally consistent with that established in the Phase III studies in nAMD, DME and RVO.1-3

About VOYAGER
VOYAGER is the largest global, prospective, non-interventional real-world study of Vabysmo (faricimab).1-3 It captures real-world data from 28 countries/regions across six continents representing more than 5,000 patients treated for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) or retinal vein occlusion (RVO).1-3 The study leverages state-of-the-art AI and deep learning algorithms to evaluate SD-OCT images captured during routine clinical practice.4-6

About Vabysmo® (faricimab)
Vabysmo is the first bispecific antibody approved for the eye.7-9 It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.9,10 Vabysmo is approved in more than 100 countries around the world, including the United States (US), Japan, the United Kingdom and the European Union (EU) for people with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema, and in more than 60 countries, including the US, EU and Japan, for people with macular edema following retinal vein occlusion (RVO).7,8,11-14 Review by other health authorities is ongoing.

About Roche in Ophthalmology
At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care.

Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Guymer R, et al. One-year Clinical and Anatomical Outcomes of Faricimab Treatment in Eyes With nAMD From the Global, Prospective Observational VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria.
[2] Sheth V, et al. One–Year Clinical and Anatomical Outcomes of Faricimab Treatment in Eyes With DME From the Global, Prospective Observational VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria.
[3] Hattenbach L-O, et al. Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Retinal Vein Occlusion From a Global, Prospective Observational Study: The VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria.
[4] Bailey C, et al. Anatomical Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Real-World Imaging from the VOYAGER Study. Presented at:26th EURETINA Congress; 1–4 October 2026; Vienna, Austria.
[5] Koh A, et al. Anatomical Outcomes of Faricimab in Patients with Diabetic Macular Edema: 12-Month Real-World Imaging from the VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria.
[6] Guymer R, Bailey C, Chaikitmongkol V, et al. Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice. Ophthalmol Sci. 2024;4(3):100442. doi:10.1016/j.xops.2023.100442.
[7] United States (US) Food and Drug Administration (FDA). Highlights of Prescribing Information, Vabysmo. April 2026. [Internet; cited September 2026]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761235s008lbl.pdf
[8] Medicines and Healthcare products Regulatory Agency approves faricimab through international work-sharing initiative. May 17, 2022. [Internet; cited September 2026]. Available from: https://www.gov.uk/government/news/mhra-approves-faricimab-through-international-work-sharing-initiative
[9] Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1.
[10] Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741-755. doi:10.1016/S0140-6736(22)00018-6.
[11] European Medicines Agency. Summary of Product Characteristics, Vabysmo. August 2026. [Internet; cited September 2026]. Available from: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf.
[12] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited September 2026]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20240326160000_1054.html.
[13] Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, for nAMD and DME. [Internet; cited September 2026]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20220328160002_909.html.
[14] Roche data on file.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50
Irène Stephan
Phone:  +41 79 377 83 75
Albert Thottiyil
Phone: +41 79 775 66 12

Attachment

Steady underlying performance against a challenging market backdrop

LONDON, October 1, 2026 – Stolt-Nielsen Limited (Oslo Børs ticker: SNI) today reported unaudited results for the third quarter and the nine months ending August 31, 2026. The Company reported a third quarter net profit of $84.4 million with revenue of $776.5 million, compared with a net profit of $64.0 million with revenue of $699.9 million in the third quarter of 2025. Net profit in the third quarter of 2026 included a gain of $15.4 million on the sale of a 50% interest in Avenir LNG Limited (Avenir LNG). The net profit for the first nine months of 2026 was $183.6 million with revenue of $2,243.6 million, compared with a net profit of $290.6 million with revenue of $2,088.4 million in the first nine months of 2025, which included $75.2 million in one-off gains related to the step-up of equity investments in Avenir LNG and Hassel Shipping 4 (HS4).

Highlights for the third quarter of 2026, compared with the third quarter of 2025, were:

  • Stolt-Nielsen Limited (SNL) consolidated EBITDA1 of $194.1 million, up from $191.7 million.
  • Earnings per share (EPS) was $1.59, up from $1.20.
  • Stolt Tankers reported operating profit of $52.1 million, down from $57.2 million.
  • Average deep-sea time-charter equivalent (TCE) revenue2 was $24,121 per operating day, compared to $24,838.
  • Stolthaven Terminals reported operating profit of $27.1 million, up from $26.3 million.
  • Stolt Tank Containers reported operating profit of $13.1 million, up from $11.7 million.
  • Corporate and Other, including Stolt Sea Farm (SSF) and Stolt-Nielsen Gas (SNG), reported an operating profit (including the impact of the fair value of biological assets adjustment) of $8.5 million, compared to an operating profit of $14.2 million.

Udo Lange, Chief Executive Officer of Stolt-Nielsen Limited, commented:

“I am pleased to report underlying operating performance broadly in line with last year, and an improvement on the prior quarter, despite a challenging macro backdrop. Global supply chains are complex, and visibility remains short. Customer conversations have evolved from supply chain efficiency to supply chain resilience. Our portfolio allows us to offer the flexibility of shipping, storage, and intermodal solutions to support our customers’ logistics needs.

“In the third quarter, Stolt Tankers earnings declined year-on-year, but were stable versus the prior quarter, with firmer average freight rates offset by lower volumes and higher bunker costs. Stolthaven Terminals increased utilisation and operating profit year-on-year. Stolt Tank Containers (STC) continues to integrate the Suttons business, increasing scale, broadening the product offering, and extending market reach. Together with margin improvement, this supported a return to an operating profit this quarter for STC.

“Stolt Magnesium was subject to an attack off Oman in July. We have insurance cover and expect minimal financial impact on the Company and, importantly, I am relieved that our seafarers suffered no physical injuries and the cargo was secured. During the quarter, we completed the sale of a 50% interest in Avenir LNG to NYK Line, creating a strategic partnership to accelerate growth in small-scale LNG and LNG bunkering.”


1 Before fair value of biological assets, gain (loss) on sales of assets and other one-time, non-cash items.
2 TCE revenue per operating day refers to deep-sea STJS sailed-in revenue per day, which is calculated as voyage revenue less voyage related expenses and trading overhead expense, divided by total operating days during the period.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

As part of exclusive negotiations, Vicat announces that it has entered into a process to acquire Cemex’s ready-mix concrete and aggregates operations located in South-Eastern France.

The proposed transaction would involve the acquisition by Vicat of the subsidiaries – Cemex Granulats Rhône Méditerranée, Cemex Béton Rhône Alpes, Cemex Béton Sud Est – operating a network of 48 ready-mix concrete plants, 9 aggregates quarries, related services and certain interests in joint ventures across the Rhône Valley and the Provence-Alpes-Côte d’Azur (PACA) region, notably along the Mediterranean corridor stretching from Marseille to Nice.

A highly complementary transaction with strong medium-term value creation potential

Given its geographical complementarity with Vicat’s existing footprint, the proposed transaction would further strengthen the Group’s regional presence in adjacent markets and generate industrial, commercial, and logistics synergies, particularly with cement business.

The transaction would also represent a significant lever to accelerate the deployment of lower-carbon solutions by enabling the Group to further control concrete mix designs and promote the use of supplementary cementitious materials incorporated into the production of low-carbon concrete.

Timeline and conditions

The preliminary Memorandum of Understanding (MoU) entered between Cemex and Vicat provides for consultation with employee representative bodies, with discussions to continue over the coming weeks to finalize the transaction documentation.
Completion of the transaction is expected before December 31, 2026 and remains subject to the prior approval of the competent competition authority under applicable merger control regulations.

Guy Sidos, Chairman and Chief Executive Officer of Vicat group, commented:

“This transaction fully aligns with our strategy of selective growth and strengthening our operating platform. It also reflects our confidence in the recovery of the French market. The assets concerned benefit from an attractive geographical positioning in South-Eastern France, spanning both the Rhône corridor and the Riviera, and are highly complementary to our existing operations. The transaction will enable us to further enhance our proximity to customers while accelerating the deployment of our lower-carbon solutions.”

The Group updates its deleveraging target for the 2026-2027 period

Having successfully completed a deleveraging phase that reduced its financial leverage from 2.8x at year-end 2022 to 1.5x at year-end 2025, the Group remains committed to disciplined balance sheet management.

Reflecting this acquisition, as well as its intention to retain the flexibility to pursue targeted value-accretive bolt-on growth opportunities, the Group has set a new financial leverage target of between 1.3x and 1.5x for the 2026-2027 period.

Contacts

Investor Relations
Pierre Pedrosa
Tel: +33 6 73 25 98 06
pierre.pedrosa@vicat.fr
Press
Raphael Hinninger
Tel: +33 7 61 74 86 52
raphael.hinninger@vicat.fr


About Vicat 

For more than 170 years, Vicat has been a leading player in the mineral and biosourced building materials industry. Vicat is a group listed on the Euronext Paris market, part of the SBF 120 Index, and is under the majority control of its founding family. With the ambition of achieving carbon neutrality in its value chain by 2050, the Vicat Group now operates three core lines of business: Cement, Ready-Mixed Concrete and Aggregates, as well as related activities. Present in 12 developed and emerging countries, the Group employs 10,500 people and has generated consolidated sales of €3,854 million in 2025. With its strong regional positions, Vicat is developing a circular economy model beneficial for all and consistently innovating to reduce the construction industry’s environmental impact.

Attachment

Octopus Apollo VCT plc

Total Voting Rights and Capital

Octopus Apollo VCT plc (‘the Company’) announces that as at 30 September 2026 its issued share capital consists of 1,186,636,110‬‬‬‬‬ Ordinary shares of 0.1p each. The Company holds no shares in treasury and the total voting rights in the Company are 1,186,636,110.

The above figure of 1,186,636,110 ‬‬‬‬‬may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For further information please contact:

Andrew Humphries
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800Y3XEIQ18DP3O53

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.